Life sciences manufacturers are entering 2026 with familiar pressures, but less margin for error.
Regulatory exposure is constant. Product complexity is rising. Workforce shortages persist. Yet, many teams remain weighed down by rigid batch records, manual documentation, and slow release cycles. Critical quality data often arrives too late — buried in retrospective deviations and investigation reports rather than preventing errors in real time.
For years, compliance has been the justification for moving slowly. That won’t hold in 2026.
As AI capabilities move from experimental pilots to the shop floor, the teams that succeed will be the ones who adapt without letting compliance become a barrier to innovation.
In this webinar, we’ll separate signal from noise to unpack what actually changed in 2025 and what to do next. We’ll focus on practical trends shaping execution, quality, and scale in validated environments.
What You’ll Learn:
- Operational Reality Check: What changed in 2025 and what it means for 2026 priorities.
- De-risking AI Adoption: How to balance innovation with safety in a regulated environment.
- Accelerating Change in Validated Environments: Strategies to modernize execution and shorten release cycles without compromising compliance.
Leave with sharper priorities and a clearer approach for the rest of 2026.
Featuring:
-
Gilad Langer
Industry Practice Lead, Tulip
-
Michelle Vuolo
Head of Quality, Tulip